Infectious Disease

IDWeek returns as a virtual meeting

September 27, 2021

Read for 1 minute

Source / information

Published by:

Disclosure:
Volberding reports that he is part of a data security and monitoring committee for Merck and advisor to Gilead.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

The IDWeek originally planned for San Diego will be a purely virtual meeting for the second year in a row due to COVID-19.

Starting Wednesday, September 29th, IDWeek will begin its second annual 24-hour pandemic session, “Chasing the Sun”, at 10am EDT. The meeting lasts until Sunday, October 3rd.

IDN0921Volberding

Editor-in-Chief of Infectious Disease News Paul A. Volberding, MD, said he believes people are “increasingly eager” to return to a face-to-face meeting format.

“I think we put up with the virtual meetings,” Volberding, a medical professor emeritus at the University of California at San Francisco, told Healio. “I think they’ve proven they can have real value, but I think at the same time, people miss the collaboration and informal sharing of data that comes from face-to-face contact, and it doesn’t quite happen in the same way.” with a Zoom meeting. “

Volberding said it might be a while before large face-to-face meetings return.

“It can never happen, or at least it can take a long time. The benefits to people who don’t have to travel, who don’t have to spend the money, may not have the means to go to a meeting far away – they will persist, “he said.

“If the pandemic is controlled better than it is now, hopefully we will still have the option to attend meetings electronically, and I think that’s a good thing,” he said. “All of that said, people are eager to get back together, no question about it.”

Volberding said he would be interested to hear about research on dolutegravir use in pregnant women, long-acting injectables, and resistance associated with PrEP therapies.

Interested participants can register for IDWeek on the website.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

ID week

ID week

Related Articles